Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
Yahoo! Finance
Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease progressionNew analysis shows atacicept improved renal function in patients with mild-to-moderate renal disease in Phase 2 study of atacicept in systemic lupus erythematosusBRISBANE, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on devel
Continue Reading